November 12, 2014 — GTCR, a private equity firm, announced Devicor Medical Products has signed an agreement to be acquired by Danaher Corp.’s Leica Biosystems, a provider of anatomical pathology solutions and automation used to advance cancer diagnostics.
Devicor specializes in products for use in breast biopsy procedures. Its products include the Mammotome Breast Biopsy System, tissue markers and related products, which, to date, have enabled more than 4 million women to have a minimally invasive breast biopsy.
Devicor began as a management partnership formed as part of GTCR's Leaders Strategy to build a leading medical device company focused on interventional procedures. In 2010, Devicor completed its initial platform acquisition with the successful corporate carve-out of the Mammotome breast care business from Johnson & Johnson. Through the complex, two-year carve-out, Devicor built dedicated manufacturing, transitioned a global business in more than 50 countries out of Johnson & Johnson, secured new regulatory permits in several countries, and reinvested heavily in new product research and development. As a result of the successful carve-out and transformation, Devicor was able to create a standalone, fully integrated global medical device business and was able to leverage its commercial platform to complete several complementary tuck-in acquisitions.
J.P. Morgan Securities LLC and Jefferies LLC served as Devicor's financial advisors and Kirkland & Ellis LLP provided legal counsel.